whatever Rituxan does, it does it outside the CNS
Cerebral rituximab uptake in multiple sclerosis. A Zr-immunoPET pilot study
http://journals.sagepub.com/doi/abs/10. ... 8517704507
Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration.
The exact mechanisms leading to this rapid effect have not yet been clarified. The aim of this positron emission tomography study was to assess central nervous system penetration as a possible explanation, using zirconium-89-labelled rituximab. No evidence was found for cerebral penetration of [89Zr]rituximab.